Advertisement
News
Advertisement

Aveo regains rights to cancer target from Merck

Thu, 09/30/2010 - 10:34am
Mass High Tech: The Journal of New England Technology

Aveo Pharmaceuticals Inc. has regained development and commercialization rights to AV-299, a drug target being tested to treat non-small cell lung cancer, from Merck subsidiary Schering Corp.

“The decision to return this program to AVEO is a result of portfolio prioritization,” said David Nicholson, Merck senior vice president and head of worldwide licensing and knowledge management, in a press release.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading